Cochrane · systematic review · CD013424
Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3‐5D
Hara, T, Hijikata, Y, Matsubara, Y, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
12
No studies
6
Included studies
NR
No studies 6 · 33.3%Ungraded 0 · 0%Very low 7 · 38.9%Low 3 · 16.7%Moderate 2 · 11.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Any anti‐osteoporotic drugs versus placebo in postmenopausal women with osteoporosis and CKD stages 3‐4
Population: postmenopausal women with osteoporosis and CKD stages 3‐4
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Vertebral fracture by radiography Any anti‐osteoporotic drugs vs placebo | RR 0.52 [0.39, 0.69] | 5 studies · 9054 participants | Low Downgraded: risk of bias, inconsistency |
Clinical fracture Any anti‐osteoporotic drugs vs placebo | RR 0.91 [0.79, 1.05] | 4 studies · 5827 participants | Moderate Downgraded: risk of bias |
Mean change in BMD of the femoral neck Any anti‐osteoporotic drugs vs placebo | no estimate extracted | 3 studies · 6081 participants | Very low Downgraded: risk of bias |
Mean change in BMD of the lumbar spine Any anti‐osteoporotic drugs vs placebo | no estimate extracted | 5 studies · 9054 participants | Very low Downgraded: risk of bias |
Mean change in BMD of the total hip Any anti‐osteoporotic drugs vs placebo | no estimate extracted | 3 studies · 3998 participants | Very low Downgraded: risk of bias |
Mean change in BMD of the distal radius Any anti‐osteoporotic drugs vs placebo | no estimate extracted | NR | No studies |
Adverse events Any anti‐osteoporotic drugs vs placebo | RR 0.99 [0.98, 1] | 5 studies · 9054 participants | Moderate Downgraded: risk of bias |
Death Any anti‐osteoporotic drugs vs placebo | no estimate extracted | 2 studies · 4973 participants | Low Downgraded: risk of bias |
QoL Any anti‐osteoporotic drugs vs placebo | no estimate extracted | NR | No studies |
Raloxifene versus placebo for postmenopausal women with osteoporosis and CKD stages 5 and 5D
Population: postmenopausal women with osteoporosis and CKD stages 5 and 5D
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Vertebral fracture by radiography Raloxifene vs placebo | no estimate extracted | NR | No studies |
Clinical fracture Raloxifene vs placebo | RR 0.33 [0.01, 7.87] | 1 study · 60 participants | Very low Downgraded: risk of bias, imprecision |
Mean change in BMD of the femoral neck Raloxifene vs placebo | MD 0.01 [0, 0.02] | 2 studies · 110 participants | Very low Downgraded: risk of bias, inconsistency, indirectness |
Mean change in BMD of the lumbar spine Raloxifene vs placebo | MD 0.03 [0.03, 0.04] | 2 studies · 110 participants | Low Downgraded: risk of bias, indirectness |
Mean change in BMD of the total hip Raloxifene vs placebo | no estimate extracted | NR | No studies |
Mean change in BMD of the distal radius Raloxifene vs placebo | no estimate extracted | NR | No studies |
Adverse events Raloxifene vs placebo | no estimate extracted | 2 studies · 110 participants | Very low Downgraded: risk of bias, imprecision |
Death Raloxifene vs placebo | RR 1 | 2 studies · 110 participants | Very low Downgraded: risk of bias, imprecision |
QoL Raloxifene vs placebo | no estimate extracted | NR | No studies |